Alumis Inc. (ALMS) stock
ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.60−0.53 (-8.65%)
Close on Nov 13, 2026Market cap $724.84MP/E –Yield –
Alumis EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Alumis's EPS for the twelve months ending Sep 30, 2026 was -$3.47. For fiscal 2025 it was -$2.86.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.86 | – |
| FY2024 | Dec 31, 2024 | -$10.38 | – |
| FY2023 | Dec 31, 2023 | -$72.08 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.73 | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.11 | -244.2% |
| Q1 FY2026 | Mar 31, 2026 | -$0.74 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.89 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.06 | – |
| Q2 FY2025 | Jun 30, 2025 | $0.77 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.82 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.73 | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.10 | – |
| Q1 FY2024 | Mar 31, 2024 | -$21.03 | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.18 | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.76 | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.13 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?